New targets for non-small-cell lung cancer therapy (Q36974703)

17 August 2017

1 reference

title

New targets for non-small-cell lung cancer therapy (English)

1 reference

17 August 2017

1 reference

Manrique Alvarez

1

1 reference

17 August 2017

Eloy Roman

series ordinal

2

1 reference

17 August 2017

Edgardo S Santos

series ordinal

3

1 reference

17 August 2017

Luis E Raez

series ordinal

4

1 reference

17 August 2017

publication date

1 October 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

1423-1437

1 reference

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Cetuximab in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Recent advances in targeted therapy for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Proteasome inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Upstream and downstream of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Autophagy for cancer therapy through inhibition of pro-apoptotic proteins and mammalian target of rapamycin signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.10.1423

10.1586/14737140.7.10.1423

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference